Praxis Precision Medicines, Inc. entered into a research collaboration and license agreement with Remagine Labs, Inc. to develop an iontophoretic transdermal patch for delivering ulixacaltamide for essential tremor. The partnership involves applying Remagine's proprietary platform to ulixacaltamide to complement its lead oral program and broaden the patient population. Praxis Precision Medicines, Inc. is a biotechnology company focused on developing precision medicine for neurological disorders.
